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Abstract Recently a protocol was established to obtain large quantities of human induced pluripotent stem cells (iPSC)-derived endothelial progenitors, called endothelial colony forming cells (ECFC), and of candidate smooth-muscle forming cells (SMFC). Here, we tested their suitability for assembling in spheroids, and in larger 3D cell constructs. iPSC-derived ECFC and SMFC were labeled with tdTomato and eGFP, respectively. Spheroids were formed in ultra-low adhesive wells, and their dynamic proprieties were studied by time-lapse microscopy, or by confocal microscopy. Spheroids were also tested for fusion ability either in the wells, or assembled on the Regenova 3D bioprinter by lacing them in stainless steel micro-needles (the ‘Kenzan’ method). We found that both ECFC and SMFC formed spheroids in about 24 hr. Fluorescence monitoring indicated a continuous compaction of ECFC spheroids, but which stabilized in those prepared from SMFC. In mixed spheroids, the cell distribution changed continuously, with ECFC relocating to the core, and showing pre-vascular organization. All spheroids had ability of in-well fusion, but only those containing SMFC were robust enough to sustain assembling in tubular structures. In these constructs we found a layered distribution of alpha smooth muscle actin-positive cells and extracellular matrix deposition. In conclusion, iPSC-derived vascular cell spheroids represent a promising new cellular material for scaffold-free biofabrication.  
 
















































circulating leukocytes [12], and neuropilin-1 (NRP1), a co-receptor with vascular endothelial growth factor (VEGF) receptor type 2, involved in endothelial signaling [7]. During this selection process, it was also discovered a population of iPSC-derived cells that present CD31 on the surface, but not NRP1. Unlike the double positive cells, these eventually express the alpha isoform of smooth-muscle-type actin, suggesting the possibility that these cells are progenitors of vascular smooth muscle cells, or of myo-fibroblasts. Although a more complete characterization of these cells is still in progress, by taking into consideration their endothelial-supportive activity within the spheroids and their integration in the tubular structures, as reported here, we suggest to similarly call them ‘smooth-muscle forming cells’ (SMFC).  Given their possible complementary role in vascular biology and tissue repair, we analyzed the preparation of spheroids from iPSC-derived ECFC and SMFC, labeled with the fluorescent protein markers tdTomato and eGFP, respectively. We tested the ability of the iPSC-derived ECFC and of their NPR1-negative SMFC counterparts to directly organize into spheroids. An additional opportunity to assess their 3D assembling capacity in meaningfully biofabricated constructs, was to use the Regenova bioprinting robot [13]. This instrument performs scaffold-free 3D assembling by replacing the biomaterial scaffolding with a mechanical support, namely a Cartesian array of microneedles (the ‘Kenzan’ method) [14, 15]. Here we report on the properties and biofabrication potential of these iPSC-derived cell spheroids, as well as their suitability for Kenzan bioprinting.   
2 Materials and methods 
 
























express eGFP (green) and tdTomato (red), respectively. Both cell types were routinely maintained in complete EGM-2 medium (Lonza).  
2.2 Spheroids formation. Labeled cells were seeded in EGM-2 in ultra-low adhesive U-bottomed 96 well plates (Sumitomo Bakelite, Tokyo, Japan). In preliminary experiments we determined that 2.5 x 104 cells/well produce within 24 h spheroids of about 0.5 mm diameter, as required for Regenova bioprinting. This initial cell number was maintained for preparation of spheroids throughout the experiments. To test their propensity for fusion, after separate formation the spheroids were placed in the same wells for up to 72 h.  
2.3 Spheroids imaging and analysis. After seeding, the plates were monitored every 4 h for 72 h in the automated microscope IncuCyte Zoom® (Essen Bioscience). At the end of the incubation the spheroids were imaged in combined transmission/fluorescence microscopy (Leica DMIL), or in a confocal Olympus FV1000 MPE microscope.  
2.4. Kenzan bioprinting. For bioprinting, we used spheroids compacted for 24 h. In brief, the Kenzan method performed by the Regenova bioprinting consists of gentle aspiration of individual spheroids from their formation wells, and placing them in contact by implantation in stainless steel micro-needles (‘kenzans’), of 170 µm in diameter (Fig. 
S1, and [14]). These microneedles are arranged in a Cartesian pattern with a hollow central space, which allowed the perfusion of fresh EGM2 medium. The construct was maintained for seven days in the needle array to enable spheroids to fuse and produce extracellular matrix, in a perfusion bioreactor operated at a flux of 4 mL/min [13].  
























3 Results  
3.1 Formation of compact vascular cell-containing cell spheroids. Seeding of NRP+CD31+ ECFC in ultralow-adhesive, U-shaped well culture plates [16, 13] produced ‘cell lawns’ with a scattered yet slightly clumped pattern (Fig. 1A top). These colonies eventually led to formation of spheroids, but they were not uniformly compacted and were imperfectly round (Fig. 1A, bottom and Fig. S2). At the same time, eGFP+/NRP1-CD31+ (SMFC) cells formed rounder discs (Fig, 1B, top), which eventually condensed in almost spherical cell clusters (Fig. 1B, bottom). For this reason, we then combined the two cell populations, to determine whether SMFC could provide the ECFC with the needed support for generation of better spheroids. Indeed, the mixed tdTomato+-ECFC/eGFP+-SMFC colonies (Fig. 1C top) eventually formed spheroids with the same compact shape (Fig. 1C, bottom) as the eGFP/NRP1-CD31+ only cells. Moreover, when we compared the frequency of imperfectly formed spheroids, we found that this was higher in ECFC-only spheroids than in SMFC-only spheroids, while the mixed colonies generated the highest number of well-rounded, compact spheroids (Fig. S2).  Time-lapse microscopy of mixed spheroids indicated that the spheroids assembling was complete at 24 h (Fig. 1D; result corroborated with data in Fig. 2). However, their composition continued to change, with an increase in the proportion of eGFP+/NRP1-CD31+ cells (Fig. 1D, compare the early and late frames), suggestive of ECFC translocation from the surface toward spheroid’s core and/or reduction of their proportion.  
























three conditions (Fig. 2A). This analysis confirmed that, although all spheroids were made from the same initial number of cells, ECFC spheroids were not only more irregular, but also smaller (compare with Figs. 1A and S2). In addition, we found that after a rapid shrinkage, the size of SMFC-containing spheroids stabilized after about 18 h, while that of ECFC-only continued to decrease (Fig. 2A). Considering the starting cross-sectional area, there were small differences in the magnitude of the effect; however, while ECFC alone (red line) kept decreasing for the duration of the experiment, the SMFC (green line) alone and mixed (purple) lines plateaued. In addition, when we compared the rates of the size changes in ECFC, we observed clear differences between these in the initial hours (Fig. 
























3.3 Cellular relocation within spheroids. One of the conspicuous properties of cell-heterogeneous spheroids is ‘cell sorting’, namely separation of cell layers based on their affinity, those with increased adhesiveness tending to compact together at the spheroid core [17]. Since (i) adult endothelial cells remain at the surface of mixed spheroids [18, 19], and (ii) ECFC manifest a reduced intercellular adhesiveness in the early stages of aggregation (Fig. 1A vs. 1B), we anticipated that ECFC would also prefer a 
superficial distribution. Instead, after initially displaying the expected surface localization, the proportion of superficial ECFC surprisingly decreased, and consequently the majority of the cells eventually visible at the exterior were those eGFP-positive (Fig. 1D). This process was confirmed by imaging the spheroids at higher magnification (Fig 3A).  Notably, Fig. 3B suggests superficial ECFC accumulations and also incipient formation of cell ‘cords’, as part of the cellular dynamics in these structures at early time points (1 day), unlike the corresponding SMFC (Fig. 3C). Optical sectioning by confocal microscopy of two weeks-old spheroids revealed an almost complete ‘cell sorting’, with cortical distribution of SMFC, and ECFC concentrated at the core (Fig. 3D-F). The structured organization of ECFC at the core of these spheroids suggested generation of cell cords (Fig. 3B), and also possible a sprouting-like activity (Fig. 3D-F).  
3.4 SMFC-containing spheroids can be assembled in larger structures by 
























‘impales’ pre-formed half-millimeter spheroids one-by-one in stainless steel microneedles (‘kenzans’[14]) (Fig. S1). Consequently, the spheroids are skewered in contact to each other, an interaction that would promote their eventual fusion in a tissue-like structure by cell translocation and further matrix secretion. In accordance with the observations in individual spheroids, the ECFC retained the ability to fuse and form cell cords after their assembling in the kenzans (Fig. 4E), unlike the co-embedded SMFC (Fig. 4F).  
3.5 Mixed bio-assembled spheroids show signs of vascular differentiation. Our attempts to permanently lace cell spheroids made only from the ECFC by this method have failed, consistent with their poor aggregation capacity (Fig. 1). Instead, those made from NRP1-CD31+ cells were more Kenzan-printable. Their consistency was strong enough to resist the gentle aspiration by the nozzle connected to the robotic arm of the bioprinter, as well as the piercing by the sharp microneedles (Fig. S1B and Fig. 4E-F). The constructs were maintained in micro-needle arrays with a hollow space, which allowed continuous perfusion of the tubular construct with fresh medium [13]. After 7 days, the tubes thus formed were removed, fixed, and either imaged as such by transmission (Fig. 4G) or fluorescence microscopy (Fig. 4H). Alternatively, the tubes were maintained another 7 days in culture, after which they aey were fixed, paraffin-embedded and immuno-stained (Fig. 5). Based on the distribution of DAPI-positive nuclei, this construct proves to be a densely-populated cellular structure, many of the cells still expressing the eGFP marker in various degrees (Fig. 4F, 5A). However, their distribution was rather sparse, with spaces likely occupied by other cells, or by an extracellular matrix rich in collagen type IV (Fig. 

















































Recently Prasain et al. established a method to produce large quantities of ECFC from iPSC [7]. This progress opens the way towards personalized biofabrication, combined with other cell types, of autologous tissue-engineered constructs. It also creates the opportunity for efficient clinical treatments by cell therapy, beyond the cardiovascular realm, of a variety of circulation-dependent diseases. Essentially, this method consists of isolation, after appropriate priming, of a subpopulation of NRP1+CD31+ cells by fluorescence activated cell sorting [7]. A class of NRP1-CD31+ cells, of less defined phenotype is produced during this operation. Unlike ECFC, these cells express smooth muscle-type actin [7]. This suggests their potential to differentiate into a vascular smooth muscle cell/fibroblast lineage.  
























3D organization and proliferation, and (iii) sustain neovascularization in vivo. Therefore, they may be used as functional vascularization units for cell therapy and tissue engineering.  Here we used ECFC as a more primitive cell type, with a higher propensity to proliferation and differentiation than the HUVEC (which as fetal tissue, are by necessity closer to the termination of their biological role). We report that ECFC have the ability to quickly aggregate in relatively round clusters in non-adhesive culture wells. However, when prepared from ECFC alone, these cell clusters were loose and their size constantly decreased. In addition, they had poor biomechanical consistency, as shown by the inability to be sustain integrity when gently aspirated with the low depression routinely used by the Regenova’s robotic arm, and to sustain the implantation in the instrument’s microneedles. To prepare more robust spheroids from ECFC only, we could have considered other methods to strengthen their intercellular interactions (such as using magnetic beads [37]), or to incorporate them in biomaterials as additional extracellular matrices [10]. However, we considered that a compact mass of cells, even at the progenitor stage, is an unusual situation for the normal epithelial physiology. Instead, we were more interested in assessing the properties in this respect of the also available NRP1-CD31+ cell population either in making spheroids by themselves, or as potential ‘carriers’ of the ECFC. Indeed, we found that SMFC formed more robust spheroids, which maintained their sturdiness even when replaced by up to 20% ECFC. Moreover, SMFC appeared to provide protection to ECFC, even after these relocated to the core of spheroids, where they seemed to further differentiate into pre-vascular cords.  
























the nozzle which takes them from the formatting wells. Also, to come in contact with each other for subsequent fusion, these spheroids need to be uniform in size and with a diameter comparable with the distance between micro-needles [14]. For these reasons, spheroid shape and size are the first ‘quality check’ on the Regenova bioprinter, wherein those non-conform to these standards are rejected out of the actual printing.  Due to the very processes leading to their formation, mainly the system’s energy decrease via maximal attraction and optimal cell redistribution [38], the spheroids continuously shrink. However, the pace of size reduction slows down or even ceases, due to the concurring forces derived from compaction (given the constant cell volume), combined with the resultant of cell turnover (i.e., cell proliferation and cell death). Therefore, finding the correct timing to attain a reasonably stable spheroid diameter is an important consideration for their optimal use in biofabrication. If the spheroids are used too early, they might not be fully formed in terms of intracellular interactions and extracellular matrix composition, and thus not enough robust during subsequent manipulation. Conversely, keeping them too long in culture could make them vulnerable to hypoxia and nutrient depletion at the core [39]. In our hands, all three spheroid types attained their relatively stable size within 18-24 h, with much of their compaction occurring during the first 3 h. This seems to be comparable, or faster than for other cells types, which for the same purpose might take several days [40].  
















































nature of ECFC as compared to EC makes them more chemotactically sensitive to the VEGF possibly generated at the hypoxic spheroid core [44].  
4.4 Biofabrication with spheroids. EC/SMC spheroids have been previously used for assembling by ‘scaffold-free biofabrication’ of vascular grafts [13], but not when derived from iPSC. This method enables the acquiring of high quantities of cells in a relatively short time, which represents a clear advantage. Therefore we verified the ability of our spheroids to fuse in the culture wells, and we also tested their ‘printability’ on the Regenova robot. Besides appropriate size and shape, the spheroids needed to be sturdy enough for handling for this method, both during uptake and their piercing by the micro-needles. While the ECFC alone did not pass this test, SMFC either alone or in combination with ECFC were capable to sustain this form of biofabrication. Large vessels are essentially composed of a thick layer of smooth muscle cells. This implies that, with further improvements, these spheroids could be eventually used as building blocks of scaffold-free biofabrication of vascular grafts. Moreover, SMFC-only spheroids could represent an interesting cellular system for cell therapy, through their ability to stimulate and/or support the micro-vascular development in vivo via paracrine factors.  
























constructs were not yet ready for biomechanical testing in vitro, or in an in vivo setting. One reason is the insufficient structural cohesion, due at least in part to the lack of elastic elements (elastin sheets and/or collagen I production), to provide them with the required resistance and compliance. In fact, these properties were insufficient even when adult smooth muscle cells and fibroblasts were used for spheroids preparation [13]. This limitation could be addressed by, e.g., (i) more specifically drive the differentiation of our cells towards a medial phenotype, or (ii) the use of ‘hybrid’ bioprinting, which would allow incorporation in the construct of stronger biomaterials, such as polymeric fibrillar scaffolds [47].  In conclusion, here we show that cell spheroids with promising properties for scaffold-free biofabrication can be prepared from iPSC-derived vascular progenitors. We found the optimal maturation time for spheroids collection, and investigated relevant cellular dynamic properties. Remarkably, the mixed spheroids demonstrated improved properties and long-term vitality at the core, and seemed to encapsulate microvascular fragments ready for larger-scale bio-assembling. In addition, we preliminarily found these spheroids’ suitability for ‘scaffold-free’ bioprinting, using the Kenzan method on the Regenova instrument.    
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Figure 4. Fusion and internal organization of iPSC-derived spheroids in wells 



























Figure 5: Characterization of a construct prepared from iPSC-derived SMFC 
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